Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA
The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one…
News
Collaboration Driving Progress: LLS Forms Alliances with Leading Cancer Institutions and Foundations to Co-Fund nearly $17 million in New Research Grants
As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the …
BioTheryX Presented Trial in Progress at ASH: A Phase I Trial of BTX-A51 in Patients with AML or High-Risk MDS
Chappaqua, N.Y., December 7, 2020 - BioTheryX, Inc., a clinical stage biotechnology company creating new classes of compounds based on multi-kinase in…
Sutro Biopharma Presents Data for STRO-001 for the Treatment of NHL and AML at ASH
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing compa…
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at ASH
WATERTOWN, Mass., Dec. 07, 2020 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deli…
Affimed Announces Updated AFM13 Clinical Data Presentation at ASH
Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their …
Kiadis announces new data at the 2020 ASH Annual Meeting and Exposition
Amsterdam, The Netherlands, December 6, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage…
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
December 06, 2020 - FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from the magrolimab Phase 1b trial. Mag…
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
CAMBRIDGE, Mass., Dec. 06, 2020 - Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters rel…
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at ASH
SAN DIEGO, Dec. 05, 2020 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medi…
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
December 05, 2020 - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 tri…
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: ASH Update
BOSTON, MA, December 5, 2020 - Verastem, Inc. (Nasdaq:VSTM), a biopharmaceutical company today presented the expansion phase initial results for COPIK…
Media resources
Email
Contact us for inquiries and interview requests.
Press Kit
Explore details for journalists and media outlets.
Brand Center
Access approved logos, guidelines, and other assets.